M. Namer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.

J. Cuzick, W. Sauerbrei, R. Blamey, 2003, European journal of cancer.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Phase II study of fotemustine in recurrent supratentorial malignant gliomas.

M. Namer, J. Derlon, M. Frénay, 1991, European journal of cancer.

Goserelin depot in the treatment of premenopausal advanced breast cancer.

R. Blamey, M. Namer, W. Jonat, 1992, European journal of cancer.

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma

C. Jacquillat, D. Khayat, P. Fumoleau, 2004, Cancer Chemotherapy and Pharmacology.

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

J. Cuzick, W. Sauerbrei, R. Blamey, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer.

R. Blamey, W. Jonat, M. Kaufmann, 1993, European journal of cancer.

Updated survival results from the Zebra trial.

J. Cuzick, W. Sauerbrei, M. Schumacher, 2002 .